ZNTL
Income statement / Annual
Last year (2025), Zentalis Pharmaceuticals Inc's total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2025, Zentalis Pharmaceuticals Inc's net income was -$137.06 M.
See Zentalis Pharmaceuticals Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00 |
$67.43 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$14.00 K |
| Cost of Revenue |
$739.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
-$739.00 K
|
$67.43 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$14.00 K
|
| Gross Profit Ratio |
0
|
1
|
0
|
0
|
0
|
0
|
0
|
1
|
| Research and Development Expenses |
$107.30 M
|
$167.77 M
|
$235.16 M
|
$172.73 M
|
$175.60 M
|
$84.90 M
|
$38.39 M
|
$18.92 M
|
| General & Administrative Expenses |
$37.72 M
|
$87.12 M
|
$59.40 M
|
$54.55 M
|
$40.94 M
|
$33.89 M
|
$8.46 M
|
$4.88 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$37.72 M
|
$87.12 M
|
$59.40 M
|
$54.55 M
|
$40.94 M
|
$33.89 M
|
$8.46 M
|
$4.88 M
|
| Other Expenses |
$0.00
|
$3.74 M
|
$4.95 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$145.01 M
|
$258.62 M
|
$299.51 M
|
$227.29 M
|
$216.54 M
|
$118.79 M
|
$46.85 M
|
$23.80 M
|
| Cost And Expenses |
$146.25 M
|
$258.62 M
|
$299.51 M
|
$227.29 M
|
$216.54 M
|
$118.79 M
|
$46.85 M
|
$23.80 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$2.26 K
|
$0.00
|
$0.00
|
$498.00 K
|
$355.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$2.58 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$739.00 K
|
$1.29 M
|
$1.39 M
|
$1.43 M
|
$544.00 K
|
$160.00 K
|
$111.00 K
|
$51.49 K
|
| EBITDA |
-$145.51 M |
-$186.17 M |
-$247.60 M |
-$225.86 M |
-$207.20 M |
-$118.63 M |
-$46.73 M |
-$23.73 M |
| EBITDA Ratio |
0
|
-2.76
|
0
|
0
|
0
|
0
|
0
|
-1695.14
|
| Operating Income Ratio |
0
|
-2.84
|
0
|
0
|
0
|
0
|
0
|
-1698.79
|
| Total Other Income/Expenses Net |
$9.63 M
|
$25.50 M
|
$6.60 M
|
-$10.30 M
|
$50.15 M
|
$683.00 K
|
$482.00 K
|
$355.00 K
|
| Income Before Tax |
-$136.62 M
|
-$165.69 M
|
-$292.91 M
|
-$237.58 M
|
-$166.39 M
|
-$118.10 M
|
-$46.36 M
|
-$23.43 M
|
| Income Before Tax Ratio |
0
|
-2.46
|
0
|
0
|
0
|
0
|
0
|
-1673.43
|
| Income Tax Expense |
$442.00 K
|
$177.00 K
|
-$601.00 K
|
-$469.00 K
|
-$297.00 K
|
$444.00 K
|
$15.00 K
|
$4.00 K
|
| Net Income |
-$137.06 M
|
-$165.84 M
|
-$292.19 M
|
-$236.81 M
|
-$158.73 M
|
-$117.84 M
|
-$45.66 M
|
-$21.07 M
|
| Net Income Ratio |
0
|
-2.46
|
0
|
0
|
0
|
0
|
0
|
-1504.79
|
| EPS |
-1.91 |
-2.33 |
-4.47 |
-4.48 |
-3.72 |
-2.87 |
-1.29 |
-1.17 |
| EPS Diluted |
-1.91 |
-2.33 |
-4.47 |
-4.48 |
-3.72 |
-2.87 |
-1.29 |
-1.17 |
| Weighted Average Shares Out |
$71.87 M
|
$71.08 M
|
$65.41 M
|
$52.86 M
|
$42.69 M
|
$41.04 M
|
$35.88 M
|
$18.06 M
|
| Weighted Average Shares Out Diluted |
$71.87 M
|
$71.08 M
|
$65.41 M
|
$52.86 M
|
$42.69 M
|
$41.04 M
|
$35.88 M
|
$18.06 M
|
| Link |
|
|
|
|
|
|
|
|
